Claims for Patent: 5,045,472

Summary for Patent: 5,045,472

Title:	Reagent mixture and composition for treating red blood cells to effect sphering
Abstract:	A composition is disclosed of blood serum sample preparation for improved, more accurate and precise, electrooptical method for measuring erythrocyte volumes, individually and as an average.
Inventor(s):	Ornstein; Leonard (White Plains, NY), Kim; Young R. (Hartsdale, NY)
Assignee:	Technicon Instruments Corporation (Tarrytown, NY)
Application Number:	07/537,887
Patent Claims:	1. A composition for use in a cytometer, comprising: (a) an anticoagulated whole blood sample aliquot, and (b) a reagent mixture consisting essentially of: (i) an isotonic aqueous solution; (ii) a sphering agent; and (iii) a protein, which reversibly binds said sphering agent; said protein and sphering agent being present in a weight ratio of protein to sphering agent from about 20:1 to about 70:1, and said sphering agent having a final concentration in the range of about 2 mg per 100 ml to about 10 mg per 100 ml in said reagent mixture. 2. The composition of claim 1, wherein said protein is a serum albumin. 3. The composition of claim 74, wherein said detergent is an alkali metal salt of an alkyl sulfate. 4. The composition of claim 3, wherein said alkali metal salt is an alkali metal lauryl sulfate. 5. The composition of claim 4, wherein said alkali metal laurel sulfate is sodium lauryl sulfate. 6. The composition of claim 74, wherein said detergent is an alkali metal salt of an alkyl sulfate, said alkyl containing from 10 to 16 carbon atoms. 7. The composition of claim 6, wherein said alkyl sulfate salt is an alkali metal lauryl sulfate. 8. The composition of claim 7, wherein said alkali metal lauryl sulfate is sodium lauryl sulfate. 9. The composition of claim 1, wherein the concentration of sphering agent is about 3 mg per 100 ml. 10. The composition of claim 1, wherein said protein and sphering agent are present in a weight ratio of protein to sphering agent of about 50:1. 11. The composition of claim 1, wherein said protein is selected from the group consisting of bovine serum albumin, human albumin, and egg albumin. 12. The composition of claim 1, wherein said protein is endogenous in a whole blood sample. 13. The composition of claim 1, wherein said sphering agent is a detergent. 14. The composition of claim 1, wherein said sphering agent is a phospholipid. 15. The composition of claim 1, wherein said sphering agent is a fatty acid. 16. The composition of claims 1, 13, 14, or 15, wherein said reagent mixture further includes a fixing agent. 17. The composition of claim 16, wherein said fixing agent is gluteraldehyde present in said reagent mixture in an amount providing a final gluteraldehyde concentration of from about 0.1% to 0.4% by weight. 18. A reagent mixture for sphering red blood cells in an anticoagulated whole blood sample, consisting essentially of: (i) an isotonic aqueous solution; (ii) a sphering agent; (iii) a protein, which reversibly binds said sphering agent; said protein and sphering agent being present in said mixture in a weight ratio of protein to sphering agent from about 20:1 to about 70:1, and said sphering agent having a final concentration in the range of about 2 mg per 100 ml to about 10 mg per 100 ml in said reagent mixture. 19. The reagent mixture of claim 18, wherein said protein is a serum albumin. 20. The reagent mixture of claim 18, wherein said sphering agent is an alkali metal salt of an alkyl sulfate. 21. The reagent mixture of claim 20, wherein said alkyl sulfate salt is an alkali metal lauryl sulfate. 22. The reagent mixture of claim 21, wherein said alkali metal lauryl sulfate is sodium lauryl sulfate. 23. The regent mixture of claim 18, wherein said sphering agent is an alkali metal salt of an alkyl sulfate, said alkyl sulfate containing from 10 to 16 carbon atoms. 24. The reagent mixture of claim 23, wherein said alkyl sulfate salt is an alkali metal lauryl sulfate. 25. The reagent mixture of claim 24, wherein said alkali metal lauryl sulfate is sodium lauryl sulfate. 26. The reagent mixture of claim 18, wherein the concentration of sphering agent is about 3 mg per 100 ml. 27. The reagent mixture of claim 18, wherein said protein and sphering agent are present in a weight ratio of protein to sphering agent of about 50:1. 28. The reagent mixture of claim 18, wherein said protein is selected from the group consisting of bovine serum albumin, human albumin, and egg albumin. 29. The reagent mixture of claim 18 wherein said protein is endogenous in a whole blood sample. 30. The reagent mixture of claim 18, wherein said sphering agent is a detergent. 31. The reagent mixture of claim 18, wherein said sphering agent is a phospholipid. 32. The reagent mixture of claim 18, wherein said sphering agent is a fatty acid. 33. The reagent mixture of claims 18, 30, 31, or 32, further including a fixing agent. 34. The reagent mixture of claim 33, wherein said fixing agent is gluteraldehyde present in an amount providing a final gluteraldehyde concentration of from about 0.1% to 0.4% by weight.

Details for Patent 5,045,472

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942		2040-01-28
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954		2040-01-28
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976		2040-01-28
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	08/15/1978		2040-01-28
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	02/17/1995		2040-01-28
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	06/11/2003		2040-01-28
Csl Behring Llc	ALBUMINAR, ALBUMINAR-20, ALBUMINAR-25, ALBUMINAR-5	albumin (human)	Injection	103955	03/17/2000		2040-01-28